Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


AbbVie showcases breadth and depth of research in Crohn’s disease and ulcerative colitis at UEG Week 2023

Written by | 14 Oct 2023

AbbVie will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from October 14-17. AbbVie… read more.

Skyrizi met all primary and secondary endpoints versus Stelara in head-to-head study in Crohn’s disease – AbbVie

Written by | 16 Sep 2023

AbbVie announced top-line results from the Phase III SEQUENCE clinical trial evaluating risankizumab (Skyrizi, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg… read more.

Inflammatory bowel disease increases risks for pregnant women

Written by | 8 Aug 2022

Pregnant women with inflammatory bowel disease (IBD) and their babies face increased risks and complications compared to pregnant women without IBD. Those are the findings from a new… read more.

Janssen presents results of first head-to-head study of biologic therapies in patients with moderate to severe Crohn’s disease

Written by | 12 Jun 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced efficacy and safety data for Stelara (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),including data from the SEAVUE… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.